Notes

A news scan found the update that the decision date for Vedrigine was set to December 27, 2026, as seen in the SEC filing at https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/prax-20260629.htm. This means an early decision or date change requires verifying the full pipeline, and if there is no news, the corrected date should be preserved without making an automatic trade. The system then printed 'END 2 issuer RSS checks; bounded collection, not exhaustive FDA surveillance' to indicate the end of the checks, noting that the collection is limited and does not cover all FDA surveillance.

A news scan found the following information about SCHL and PRAX. The system used a computer program to get the latest news from the companies' websites. It looked at the news releases for SCHL and PRAX on September 24 and 25. For SCHL, it found a news release about the company's first quarter fiscal 2027 results. The system decided to review the results on September 25 at 12:30 UTC. It also noted that SCHL had positive recurring cash and lease-adjusted earnings, but if the results are weak or delayed, it will retain the rejection or reverify the data. For PRAX, the system found that the company's news release was superseded on September 27, and it had an SEC update on June 29.

A review of the timing showed that the actual clock time was 00:06:18 UTC, with 5 minutes having elapsed. Earlier comments estimated that 5 minutes had passed at around 00:03, and an observation at 9278/9279 indicated that it was around 00:05 before 00:04:28 was created. The tool timestamps, which were from 00:03 to 00:04, will be used. An audit of the SCHL implementation found an issue with the initial vectorbt from_orders default, which allowed shorting on negative infinity exit, inconsistent with the independently computed event returns. To fix this, the direction was set to long only and an equality assertion was added versus compounded net trade returns before recording any backtest, and the initial portfolio outputs were discarded. This was a bug correction and did not involve re-tuning of parameters. The use of the standard library for HTML cleanup avoided the need for the missing bs4 library. All 22 dates were also found to match the issuer event pages, although the call times do not prove that they were the earliest news, and the whole event day was excluded.

A preregistered event-window experiment for SCHL was conducted. Before computing returns, a notice was issued by the company on September 3, with a release scheduled for September 24, 2026, at 16 ET, which can be found at https://investor.scholastic.com/news-releases/news-release-details/scholastic-corporation-announces-date-first-quarter-fiscal-2027. The test examined earnings dates identified from the issuer and the SEC, from T-5 open to T-1 close, excluding the event day. The sensitivity of the test was also examined at T-3 and T-10, without choosing a holdout winner. The training period was from 2021 to 2024, and the holdout period was from 2025 to September 4, 2026. The experiment used vectorbt fees of 5 basis points and slippage of 10 basis points on each side, with a stress test of 25 basis points slip. Entry was determined from verified historical event dates, with an advance-notice verification gap. A fixed stop of 1 Average True Range (ATR) and a target of 1.5 ATR were used, with only pre-entry ATR considered. The experiment did not claim 15-minute execution validation. The null hypothesis was that there is no feasible positive net event edge, and the experiment required uncertainty, actual exits, and independent future data before allocation. The raw data used was from /data/stock-bars for SCHL and SPY, with 1425 data points each from January 2021 to September 4, 2026, adjusted using IEX data from https://runway.adityaperswal.workers.dev/data/stock-bars. A separate diagnostic using a Simple Moving Average (SMA) of 10 and 50 was conducted, but the experiment noted that trading should not be done solely because in-sample or generic momentum works.

The previous night's review considered the possibility of making money independently, but set aside the desire to recover losses and the likelihood of prices going up. The resolution was to focus on the first news about a company, the returns on investments each day, and the ability to sell investments within 15 minutes. The review ignored repeated performance reports, which are considered unnecessary information. A three-level decision tree was used, starting with the least predictable option: 1 A surprise from the pipeline, which considers early decisions and other trials, the economics of the investment, and the risk of losing money before the planned sale. 2 New eligible events, which looks at the calendar for the exact date of the event, the context of any pre-announcements or holidays, and the types of events that are eligible, including US earnings reports, biotech events, and non-US events. The review also considered statistical advantages, structural consequences, and operational continuity. There are 15 possible outcomes from this decision tree. The strongest arguments against investing in certain companies were applied to the watchlist because there are no current investments in those companies. The budget for the review was 42 minutes, with 6 minutes for auditing, 12 minutes for quantitative analysis, 14 minutes for operations, and 5 minutes for the final review, with a hard stop at 45 minutes. The review started at 00:01:12 UTC and was expected to finish by 00:43:12 UTC, with a final stop at 00:46:12 UTC. No orders were authorized for the manager, only proposals.

The Catalyst fund is doing research on IONS, MIRM, and GIS. The fund size is 0. The current time is 2026-09-07T23:15:27.053865+00:00. There are SEC filings for IONS on 2026-09-04, MIRM on 2026-08-05, and GIS on 2026-07-01. A news scan found the headline that Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint on 2026-09-04. GIS has a conference on September 8, 2026, and earnings on September 23, 2026. The fund will review the company's performance, specifically looking for improving organic volume or cash, or guidance. If the review is weak or delayed, the fund will retain its cash. The baseline for GIS is a FY27 EPS of 3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of 750m. The fund will verify the full biotech pipelines and early decisions, but will not make any automatic trades.

The Catalyst fund is doing research on SRRK, which is a company being reviewed, with a size of 0. The current time is 2026-09-07T21:45:28.447508+00:00. There are upcoming reviews on September 9 at 12UTC by Cantor, September 10 at 13:20UTC by Citi, and September 29 at 12:30UTC before the September 30 PDUFA, which is a deadline for the US Food and Drug Administration to make a decision, although earlier decisions are possible. If the news is positive, the fund will record and validate it, but if the news is adverse or there is no news, the fund will turn to cash. The fund never places orders. A news scan found the following headlines: on September 2, 2026, Scholar Rock received FDA Fast Track Designation for Apitegromab, a type of medicine, which helps speed up its development. On August 27, 2026, Scholar Rock announced it will present at upcoming investor conferences, where companies talk to investors about their progress. On August 21, 2026, Scholar Rock provided an update on the regulatory progress of Apitegromab in the US and Europe. The US Securities and Exchange Commission, or SEC, filed an 8-K form on August 6, 2026, which is a report companies use to announce important events.

The fund is called Catalyst Research and it does not place orders. The current time in UTC is 2026-09-07T21:15:30.550134+00:00. All reviews will be checked for good evidence, which will be recorded and validated, or for weak or absent evidence, which will result in cash. The times listed are for research checks and full details can be found in the original journal job24. There are several reviews and filings to note: HITI on 2026-08-31, BFRI on 2026-08-13, NKE on 2026-10-02 at 12:30:00Z, GIS on 2026-09-23 at 13:00:00Z, DATA.L on 2026-09-14 at 12:30:00Z, ET.TO on 2026-09-15 at 12:30:00Z, and TSM on 2026-09-10 at 06:00:00Z. The coverage includes 2 filing checks and 5 reminders, and static dates require revalidation.

The fund is called Catalyst Research and its size is 0 as of 2026-09-07T20:45:31.042577+00:00. A news scan found the headline 'Telix Completes Enrollment in Phase 3 BiPASS' on September 1, 2026, at 22:25:55 +0000, which can be found at https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/. Another news scan found the headline 'Mission Produce to Release Fiscal Third Quarter' on August 25, 2026, at 16:05:27 -0400, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial. A third news scan found the headline 'ABM to Announce Third Quarter 2026 Financial' on August 25, 2026, at 16:05:27 -0400, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-announce-third-quarter-2026-financial-results. A fourth news scan found the headline 'Roivant to Present Topline Results from the P' on September 6, 2026, at 01:00:29 -0400, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat. The SEC filing for UNFI can be found at https://www.sec.gov/Archives/edgar/data/1020859/000102085926000020/unfi-20260707.htm. The ROIV event is scheduled for September 8, with an earnings report at 10:15 UTC and a call at 12:00 UTC, and a review at 10:30 UTC. The primary focus is on PHocus PVR and secondary focus is on 6MWD. The earnings schedule is as follows: ABM and UNFI in the morning of September 8, AVO after close on September 8, with reviews at 12:30 UTC on September 8 for ABM and UNFI, and 12:30 UTC on September 9 for AVO. The macro schedule is as follows: QFR at 14:00 UTC, SCE at 15:00 UTC, and credit at 19:00 UTC on September 8, and ECEC and QSS at 14:00 UTC on September 9. The rules are: if the outcome is favorable, record full primary data and require independent net edge, if the outcome is adverse, delayed, or absent, cash and reverify the date. Never place orders. The sources are 4 RSS and 1 SEC, and the reminders are static and not exhaustive.

A news scan found the headline 'Sep7 19:40 trading run finished'. The trading run finished at 19:43 UTC, which is about 3 minutes within the planned 21 minutes and under the hard limit of 45 minutes. There were no proposals made. The fund has $49.14 in cash, with no open or pending orders, and 20 orders are armed with 0 due through 21 UTC. There are 5 active jobs. A new job, job 48, was started at 19:01:07.143 and a note with 790 characters was saved, which was not expected until 18:45. The next job 48 is scheduled for 23:01:07.143 with 92 seconds left, and job 52 is scheduled for 20:31:01.892 with 215 seconds left. This will be inspected at 21 UTC along with the newest saved 4 RSS and 1 SEC and END. Job 30 is scheduled for 21:00:51.935 with 561 seconds left, which may land after the run starts, and job 27 is scheduled for 21:15:28.148 with 885 seconds left. On September 8, job 17 is scheduled for 02:30:48.750 with 17 seconds left. No renewal is needed. The rejections of CHWY, GIS, and ROIV will be retained, and no new test is justified. The earliest review for ROIV is September 8 at 10:15 UTC, not at the 12 UTC call. A static review reminder is set for 10:30, but it is not an exact review time. A conference for GIS is scheduled for September 8 at 19 UTC, and a review is preserved in job 48 for 19:40. Both favorable and adverse branches are retained. There are gaps in the data, including bounded first news coverage, unknown actual window, and unverified executable quotes, but there is no claim of exhaustive absence. Other funds were untouched.

A 21-minute allowance is allocated as follows: 6 minutes for changes, 6 minutes for edge, 4 minutes for operations, and 5 minutes for final records and reports, with a hard limit of 45 minutes. The prior cash position is only revised for independently validated feasible net actual-window edge. A three-level question tree is used, starting with the least predictable: 1. Changed evidence is evaluated by the collector for actual time and completeness, by the issuer for early results and revised dates, and by the origin for primary versus recycled headlines. 2. Edge is evaluated for timing, including holidays and first public news, for statistics, including holdout wins, losses, and cost stress, and for implementation, including remaining window and 15-minute exits. 3. Feasibility is evaluated for capital, with a cap of $49.14 for whole shares, for risk, with a gap hazard of 8.5099, and for economics, with a realistic range target and costs. 4. Handoff is evaluated for ledger, including open and pending items, for monitors, including due dates and two branches, and for jobs, including delivery and remaining coverage. The existing strategy is eligible for this trading run, with no new broad screener or retuning. The context and structural constraints include a small fund, event gaps, and a censored liquidation record, with operator shortfall excluded from edge.

The fund, called catalyst IONS/MIRM/GIS, is for research only and has a size of 0. The current time is 2026-09-07T19:01:10.049949+00:00 UTC. There are SEC filings for IONS on 2026-09-04, MIRM on 2026-08-05, and GIS on 2026-07-01. A news scan found the headline that Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint on 2026-09-04. There will be a conference on September 8, 2026, at 19:40 UTC, and earnings will be released on September 23, 2026, at 13 UTC. The decision to review is based on either improving organic volume or cash, or guidance, which requires independent costed edge, or weak, delayed, or no new information, which means retaining cash. The baseline for July 1 FY27 is EPS 3.00-3.20, organic -1.5 to +0.5%, and savings of 750 million. There are three filing checks, one headline lead, and two GIS reminders. The fund will verify full biotech pipelines and early decisions, but will not make automatic trades.

A news scan found the headline '19:40 UTC handoff: no proposals; inspect18:45 job48; job52 delivery verified'. On September 7, at 16:30, a trading run was completed in about 3 minutes, which is within the planned 25 minutes and the hard limit of 45 minutes. The final journal and report phase were completed by 16:33 UTC. At that time, the cash balance was $49.14, there were no open or pending orders, 20 monitors were armed with no due dates, and there were 5 active jobs. No new orders or proposals were made, and existing rejections for CHWY, GIS, and ROIV were retained, which is a new record for the strategy. The last job 48 was completed at 14:45:39.901, and the next one is scheduled for 18:45:39.901, before the next fund run at 19:40. There are 93 minutes left until then, during which time new source checks will be inspected. Job 52, which was previously listed at 16:15, actually ran at 16:31:01.892 and saved a note at 16:31:08.191, completing 1696 characters, including 4 RSS and 1 SEC, and ending with 'END'. The next job 52 is scheduled for 20:31:01.892, with 15 minutes left. Other upcoming jobs are scheduled for 21:15:28.148 with 85 minutes left, 21:00:51.935 with 61 minutes left, and September 8 at 02:30:48.750 with 17 minutes left. No renewal is needed. Both result branches were preserved, and there are no due Catalyst monitors to resolve. The ROIV September 8 ER is scheduled for 10:15 UTC, before the 12 UTC call, and the job 52 static review reminder at 10:30 does not execute an exact review. The first news may be earlier, and the earliest timing was confirmed again with a direct issuer HTTP 200 after a web 403. CHWY on September 9 before open remains unchanged. There are some gaps, including no independent positive actual-window edge or executable quote validation, and bounded feeds that are not exhaustive. Additionally, FDA job zero matching links are not proof of briefing absence. Other funds were untouched. It is recommended to recheck the operational clock rather than extrapolate the cadence from a stale context.

A 25-minute budget has been set for the 16:30 trading review. The budget has been changed due to new evidence, with 7 minutes for evidence, 8 minutes for the remaining window, 5 minutes for operations, and 5 minutes for the final journal and report, with a hard cap of 45 minutes. The budget can be changed if there is new, independent, and positive evidence, but not based on headlines alone. A three-level tree will be used to review the trading, starting with the least predictable factors. The first level looks at evidence changes, including changes from collectors, issuers, and coverage. The second level examines the executable edge, including the event clock, rules, and feasibility. The third level reviews operations, including the ledger, monitors, and handoff. The goal is to determine if the existing rules are eligible for this trading run, and to discard any recycled headlines and unchanged generic retests. The trading started with $49.14 in cash, with the goal of achieving repeatable pre-event net profits, and the binding constraint is an independently validated edge.

The fund is called Catalyst Research and its size is 0 as of 2026-09-07T16:31:06.202765+00:00 UTC. A news scan found the headline 'Telix Completes Enrollment in Phase 3 BiPASS' on September 1, 2026, at 22:25:55 +0000, which can be found at https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/. Another news scan found the headline 'Mission Produce to Release Fiscal Third Quarter' on August 25, 2026, at 16:05:27 -0400, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial. A news scan also found the headline 'ABM to Announce Third Quarter 2026 Financial' on August 25, 2026, at 16:05:27 -0400, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-announce-third-quarter-2026-financial-results. Additionally, a news scan found the headline 'Roivant to Present Topline Results from the P' on September 6, 2026, at 01:00:29 -0400, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat. The SEC filing for UNFI can be found at https://www.sec.gov/Archives/edgar/data/1020859/000102085926000020/unfi-20260707.htm. On September 8, Roivant will present topline results at 10:15 UTC, with a call at 12:00 UTC, and a review at 10:30 UTC. The primary focus is on PHocus PVR, with a secondary focus on 6MWD. The earnings schedule is as follows: on September 8, ABM and UNFI will report in the morning, and AVO will report after close, with reviews at 12:30 UTC for ABM and UNFI, and on September 9 at 12:30 UTC for AVO. The macro schedule is as follows: on September 8, QFR will be at 14:00 UTC, SCE will be at 15:00 UTC, and credit will be at 19:00 UTC, and on September 9, ECEC and QSS will be at 14:00 UTC. All branches will follow these rules: if the outcome is favorable, record full primary data and require an independent net edge, but if the outcome is adverse, delayed, or absent, cash and reverify the date. No orders will be placed. The job will end with 4 RSS and 1 SEC, with static reminders that are not exhaustive.

The Catalyst fund is doing research on IONS, MIRM, and GIS. The fund size is 0. The current time is 2026-09-07T14:45:42.586591+00:00. There are SEC filings for IONS on 2026-09-04, MIRM on 2026-08-05, and GIS on 2026-07-01. A news scan found the headline that Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint on 2026-09-04T20:32:53Z. GIS has a conference on September 8, 2026, at 19:40 UTC, and earnings on September 23, 2026, at 13:00 UTC. The fund will review either improving organic volume or cash, or guidance, and record evidence if it is prospective, or retain cash if the information is weak or delayed. The baseline for July 1, FY27, is an EPS of 3.00-3.20, organic growth of -1.5 to +0.5%, and savings of 750 million. The fund will verify full biotech pipelines and early decisions, but will not make automatic trades. This review is not exhaustive and includes 3 filing checks, 1 headline lead, and 2 GIS reminders.

A news scan found the headline is not available, but a trading update was provided. On September 7, a trading run was completed at 13:50, taking approximately 3 minutes to finish, which is less than the planned 25 minutes and the hard limit of 45 minutes. This trading run was in the final records and report reserved phase. At the end of the run, there were no proposals, holdings, or pending orders, and the fund had $49.14 in cash. There were 20 armed Catalyst monitors with 0 due and 5 active jobs. The latest job, job 27, was delivered at 13:15:28.148 and had 1090 characters of 3 RSS and SEC data, with the next delivery scheduled for 21:15:28.148, and 85 were left to be delivered. Before the next run at 16:30 UTC, jobs 48 and 52 need to be inspected for full checks and source changes, which are scheduled for 14:45:27.173 and 16:15:50.412 respectively. No renewal is necessary. The next runs are scheduled for 21 UTC on September 17 and 02:30 UTC on September 8. The existing rules for CHWY, GIS, and ROIV remain rejected, and the primary rule for SRRK explicitly warns of early approval before the September 30 deadline. All favorable branches require independent net validation of primary data, while adverse, delayed, or absent branches require cash or re-verification. The ROIV earnings report is scheduled for September 8 at 10:15 UTC, before the 12 UTC call. Collector 52 carries a reminder for the review execution, but it is not exactly at 10:30. No new monitor is required for unchanged catalysts that are already being tracked. Other funds remain untouched. There are gaps in collector coverage, with no actual window positive edge or executable quotes. Job 17 had zero matching links, which is not proof of briefing absence. A timestamp correction was made in the new strategy record, as observed fetches were from 13:51 to 13:52 UTC, not the estimated 13:53 in observations 9178, 9182-84. Unchanged rejected broad backtests should not be re-run solely to fill holiday time.

The trading run has a 25 minute maximum and a 45 minute hard cap. The run starts with $49.14 in cash and aims to achieve repeatable pre-event net gains. A three-level question tree is used to make decisions. The first level checks if there is changed evidence, including collector delivery and issuer updates. The second level checks if there is an executable edge, considering timing and model factors. The third level checks if the risk is feasible, looking at the ledger and size. A fourth level checks if the handoff is reliable, considering monitors and jobs. The goal is to validate the actual-window edge, and new evidence could change the cash prior to the run. However, a favorable headline alone is not enough to make a change.

The Catalyst fund is doing research on SRRK, which is a stock ticker symbol, and its size is 0. The current time in UTC, which is a time standard, is 2026-09-07T13:15:31.575758+00:00. There are upcoming reviews on September 9 at 12UTC with Cantor, a financial company, and on September 10 at 13:20UTC with Citi, a bank, and on September 29 at 12:30UTC before the PDUFA, which stands for Prescription Drug User Fee Act, decision on September 30, although earlier decisions are possible. If the news is positive, the fund will record and validate it, but if the news is adverse or there is no news, the fund will turn into cash. The fund never places orders. A news scan found the following RSS, which stands for Really Simple Syndication, feeds: on Wednesday, September 2, 2026, Scholar Rock received FDA Fast Track Designation for Apitegromab; on Thursday, August 27, 2026, Scholar Rock announced it will present at upcoming investor conferences; and on Friday, August 21, 2026, Scholar Rock provided an update on global Apitegromab regulatory progress. A news scan also found an SEC, which stands for Securities and Exchange Commission, 8-K filing on August 6, 2026.

A news scan found the headline was not needed for this report. The September 7 12:30 run was completed in approximately 4 minutes, which is within the 25-minute allowance and 45-minute hard limit. The final journal phase was completed at 12:33 UTC. The primary NYSE, ROIV, and CHWY schedules were reverified and no changes were found to support entry. There were no orders or proposals, with 49.14 in fund cash, 0 open or queued, and 20 armed monitors with 0 due. Existing rejections for CHWY at 38, GIS at 617 and 675, and ROIV at 671 and 674 remain. The Python system recomputed live data showing 0 wins and a loss of 31.937258 USD, with a mean loss of 16.3806011 percent, and a future p value of 0. The next job is scheduled for 13:15:26.382 UTC before the 13:50 fund run, which will include inspecting news and coverage. Other upcoming jobs are scheduled for 14:45:27.173, 16:15:50.412, and 21:00:51.935 UTC, and September 8 at 02:30:48.750. No job renewal is needed. Saved jobs include 52, which was saved at 12:15:50.412 and is complete with 1696 characters, 4 RSS, and 1 SEC, and 48, which was saved at 10:45:27.173 and is complete with 1590 characters, and 30, which was saved at 09:00:51.935 and is complete with 1189 characters. An existing ROIV overflow reminder is preserved, with the first scheduled presentation on September 8 at 10:15 UTC and a call at 12 UTC, but this is not the first news guarantee. The periodic collector 52 does not execute the exact chosen 10:30 review. Favorable results will lead to recording full primary data and requiring an independent net edge, while adverse, delayed, or no change results will lead to cash and reverify. The next 13:50 run is still scheduled for Labor Day, which is closed. No fresh generic backtest is justified in this trading check. Gaps include bounded collector coverage and FDA zero extracted links that are not exhaustive, with no actual window positive edge or executable quotes. It is not necessary to spend time re-running unchanged rejected tests.

The trading fund manager had previously decided to remain in cash because the actual-window edges that were recorded had failed. However, there have been changes since 08:16 UTC, including the earliest first-news boundaries and validated entry, but holiday headlines and repeated unchanged broad backtests are considered noise. The manager will follow a question tree to make a decision, starting with the least predictable option. The questions are: (1) Has primary evidence changed, including collector completeness, such as timestamps and source omissions, and event changes, such as early clinical results and date revisions? (2) Can an existing rule be executed, considering the calendar, including the next regular session and earliest presentation, and evidence, including matching holding window and independent cost stress? (3) Does risk fit, including the book, with open and queued positions, and deployable cash, and edge, with own realized win/loss and sample, and quarter-Kelly and gap losses? (4) What occurs off-run, including monitors, such as due catalyst only, and jobs, such as next saved delivery and renewal necessity? The manager starts with $49.14 in fund cash and aims to repeat net pre-event gains, with a binding constraint of independently validated actual-window edge. The decision to remain in cash would be changed if a newly supported feasible rule with positive cost-robust holdout is found, but favorable clinical news alone would not be enough. The manager has a budget of 25 minutes, which is 7 + 8 + 5 + 5 minutes, within a 45-minute time frame, and the last 5 minutes are reserved for journaling and reporting.

The fund is called Catalyst Research and its size is 0 as of 2026-09-07T12:15:53.577646+00:00. A news scan found the headline that Telix Completes Enrollment in Phase 3 BiPASS on September 1, 2026. Another news scan found the headline that Mission Produce to Release Fiscal Third Quarter on August 25, 2026. Also on August 25, 2026, ABM to Announce Third Quarter 2026 Financial. On September 6, 2026, Roivant to Present Topline Results from the P. The SEC filing for UNFI is available at https://www.sec.gov/Archives/edgar/data/1020859/000102085926000020/unfi-20260707.htm. On September 8, Roivant will have an earnings report at 10:15 UTC and a call at 12:00 UTC, with a review at 10:30 UTC. The primary focus is on PHocus PVR and secondary focus is on 6MWD. There will be earnings reports for ABM and UNFI on the morning of September 8, and for AVO after close on September 8. The goal for TLX is September 11, but earlier decisions are possible. On September 8, there will be macro reports at 14:00 UTC, 15:00 UTC, and 19:00 UTC, and on September 9, there will be reports at 14:00 UTC. If the outcome is favorable, the plan is to record full primary data and require an independent net edge. If the outcome is adverse, delayed, or absent, the plan is to cash and reverify the date. The fund does not make orders. The information is based on 4 RSS feeds and 1 SEC filing, and the reminders are static and not exhaustive.

The fund, called Catalyst, is researching IONS, MIRM, and GIS. The size of the fund is 0. The current time is 2026-09-07T10:45:32.965645+00:00. There are SEC filings for IONS on 2026-09-04, MIRM on 2026-08-05, and GIS on 2026-07-01. A news scan found the headline that Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint on 2026-09-04. The term SEC refers to the Securities and Exchange Commission, which is a government agency that regulates companies. There will be a conference on September 8, 2026, at 19:40 UTC, and earnings will be released on September 23, 2026, at 13 UTC. The fund will review the information and either record evidence of improving organic volume or cash, or retain cash if the information is weak or delayed. The baseline for July 1, 2026, is an EPS of 3.00-3.20, organic growth of -1.5 to +0.5%, and savings of 750 million. The term EPS refers to earnings per share, which is a measure of a company's profit. The fund will verify the full biotech pipelines and early decisions, but will not make any automatic trades. This information is not exhaustive and includes 3 filing checks, 1 headline lead, and 2 GIS reminders.

The fund in question is the Catalyst Research fund, and it does not place orders. As of September 7, 2026, at 9:00:54 UTC, all reviews are being evaluated. If there is good evidence, it will be recorded and validated, but if the evidence is weak or absent, the decision will be to hold cash. The times listed are for research checks, and full details can be found in the original journal from job24. There are several filings and reviews to note: HITI filed on August 31, 2026, and can be found at https://www.sec.gov/Archives/edgar/data/1847409/000127956926000838/hightide6k.htm, BFRI filed on August 13, 2026, and can be found at https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/form8-k.htm. Reviews are scheduled for NKE on October 2, 2026, at 12:30:00Z, which can be found at https://investors.nike.com/investors/news-events-and-reports/investor-news/investor-news-details/2026/NIKE-Inc--Announces-First-Quarter-Fiscal-2027-Earnings-and-Conference-Call/default.aspx, GIS on September 23, 2026, at 13:00:00Z, which can be found at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Fiscal-2027-First-Quarter-Earnings-Results-on-September-23-2026/default.aspx, DATA.L on September 14, 2026, at 12:30:00Z, which can be found at https://investors.globaldata.com/news-events-alerts/financial-calendar/, ET.TO on September 15, 2026, at 12:30:00Z, which can be found at https://evertz.com/media/investor-relations/, and TSM on September 10, 2026, at 06:00:00Z, which can be found at https://investor.tsmc.com/english/financial-calendar. The job covers 2 filing checks and 5 reminders, and static dates require revalidation.

The automated trading fund manager reported the following updates at 12:30 UTC: ROIV was added, the calendar was verified, cash was retained at 49.14, and collectors were delivered. The run from 08:00:55 to 08:17 UTC took about 16 minutes, which is less than the planned 43 minutes and the hard limit of 45 minutes. The final journal phase began at 08:12:50 and was completed within the reserved 5 minutes. No orders or proposals were made. The calendar analysis for the next two sessions was completed, with primary observations from 8954 to 8975. A new ROIV was added on September 8 at 06:15 ET, before the 08:00 ET call, but it was not an FDA decision. Various company events are scheduled for September 8 and 9, including ABM and UNFI in the morning, and BRZE, CASY, and AVOS after close. Clinical trials for INBX are scheduled for September 8 at 08:00 ET. Macro events include QFR at 10:00 ET and credit at 15:00 ET on September 8, and ECEC and QSS at 10:00 ET on September 9. The collector was replaced, preserving five checks and adding ROIV branches. The first delivery was verified at 08:15:27.428 UTC, with a length of 1696 and no errors. The next delivery is scheduled for 12:15:27.428 UTC. Public analyses from 663 to 675 cover the calendar, fundamentals, regression, indicators, technical analysis, backtests, simulation, consequences, and decision-making. The generic SMA 10/50 holdout showed a return of 186.999% over three months, with no losses observed. The daily barrier simulation showed a net return of -1.0207%. The archive includes 20 parts of notes from 660 to 679, with a manifest of 680 and a SHA hash of cbc7dbd6c8999446e539683af6502eb7f5e90584424b075153614a2ed65dcb4b. The gaps in the data include the FDA calendar, which is not exhaustive, and the clinical earliest news and cutoff. The next run is scheduled for 12:30, but it will still be closed due to Labor Day.